Holding(s) in Company

RNS Number : 4170V

Immupharma PLC

28 October 2014

 

28 OCTOBER 2014

ImmuPharma PLC

NOTIFICATION OF AVIVA'S MAJOR INTEREST IN SHARES

Following the Successful £3.4m Fund Raising

ImmuPharma PLC (LSE:IMM), ("ImmuPharma" or the "Company"), the specialist drug discovery and development company, is pleased to confirm that  its long standing shareholder Aviva plc ("Aviva") and its subsidiaries has notified the Company that it has increased its shareholding in ImmuPharma Ordinary Shares to 8,143,876 representing a 9.19% shareholding in the Company.

This follows last week's announcement from ImmuPharma that Aviva was the lead investor in a £3.4 million fund raising to support the pivotal phase III progress of Lupuzor^TM, the Company's lead candidate for the treatment of lupus, a potentially life threatening auto-immune disease.

 Commenting on the announcement, Richard Warr, Chairman said: "We are delighted to have received further endorsement from Aviva for supporting our plans to take  Lupuzor^TM through its pivotal Phase III development." 

The full TR1 form is shown at the end of this announcement.

For further information please see the Group's web site, www.immupharma.com, or contact:

ImmuPharma plc	+ 44 (0) 20 7152 4080
Dimitri Dimitriou, Chief Executive Officer
Dr Robert Zimmer, President and Chief Scientific Officer
Richard Warr, Chairman
Tracy Weimar, Vice President, Operations and Finance
Lisa Baderoon, Head of Investor Relations	+ 44 (0) 7721 413496
Panmure, Gordon & Co., NOMAD & Broker	[phone]
Hugh Morgan, Fred Walsh, Duncan Monteith

For filings with the FCA include the annex
For filings with issuer exclude the annex
TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARESi

1. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached: ii				Immupharma plc
2. Reason for the notification (please tick the appropriate box or boxes):
An acquisition or disposal of voting rights					√
An acquisition or disposal of qualifying financial instruments which may result in the acquisition of shares already issued to which voting rights are attached
An acquisition or disposal of instruments with similar economic effect to qualifying financial instruments
An event changing the breakdown of voting rights
Other (please specify):	CHANGE TO THE NUMBER OF VOTING RIGHTS IN ISSUE, FOLLOWING THE RECENT PLACING				√
3. Full name of person(s) subject to the notification obligation: iii		Aviva plc & its subsidiaries
4. Full name of shareholder(s)  (if different from 3.):iv		Registered Holder: BNY Norwich Union Nominees Limited       232,080* Chase (GA Group) Nominees Limited        6,982,205* *denotes direct interest        Chase (GA Group) Nominees Limited           351,098 Chase Nominees Limited                                172,211 Vidacos  Nominees Limited                            406,282
5. Date of the transaction and date on which the threshold is crossed or reached: v		23 October 2014
6. Date on which issuer notified:		24 October 2014
7. Threshold(s) that is/are crossed or reached: vi, vii		4% to 8% change at Direct Interest Level

8. Notified details:
A: Voting rights attached to shares viii, ix
Class/type of shares if possible using the ISIN CODE	Situation previous to the triggering transaction				Resulting situation after the triggering transaction
	Number of Shares		Number of Voting Rights		Number of shares	Number of voting rights			% of  voting rights x
					Direct	Direct xi		Indirect xii	Direct		Indirect
Ordinary Shares GB0033711010	4,388,986		4,388,986		8,143,876	7,214,285		929,591	8.14%		1.05%
B: Qualifying Financial Instruments
Resulting situation after the triggering transaction
Type of financial instrument		Expiration date xiii		Exercise/ Conversion Period xiv			Number of voting rights that may be acquired if the instrument is exercised/ converted.			% of voting rights

C: Financial Instruments with similar economic effect to Qualifying Financial Instruments xv, xvi
Resulting situation after the triggering transaction
Type of financial instrument	Exercise price	Expiration date xvii	Exercise/ Conversion period xviii	Number of voting rights instrument refers to	% of voting rights xix, xx
					Nominal	Delta

Total (A+B+C)
Number of voting rights	Percentage of voting rights
8,143,876	9.19%

9. Chain of controlled undertakings through which the voting rights and/or the financial instruments are effectively held, if applicable: xxi
The voting rights are managed and controlled by Aviva Investors Global Services Limited, with the following chain of controlled undertakings:- Aviva Investors Global Services Limited: ·      Aviva plc (Parent Company) ·      Aviva Group Holdings Limited (wholly owned subsidiary of Aviva plc) ·      Aviva Investors Holdings Limited (wholly owned subsidiary of Aviva Group Holdings Limited) ·      Aviva Investors Global Services Limited (wholly owned subsidiary of Aviva Investors Holdings Limited)
Proxy Voting:
10. Name of the proxy holder:		See Section 4
11. Number of voting rights proxy holder will cease to hold:
12. Date on which proxy holder will cease to hold voting rights:
13. Additional information:	Figures are based the total number of voting rights of  88,622,463 as per the recent 'Additional Listing' announcement of 21 October 2014.
14. Contact name:	Neil Whittaker, Aviva plc
15. Contact telephone number:	01603 684420

 

END

 

 

HOLKDLFLZBFLFBF